Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Invest in Cases Systematically - Every stock is handpicked
Start Buying Now
Start Buying Now
BSE: 0 | NSE: UNIHEALTH | Hospital & Healthcare Services | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Unihealth Consultancy Ltd is a below average quality company.
The key valuation ratios of Unihealth Consultancy Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Unihealth Consultancy Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|
| ROCE % ⓘ | -3.5% | 7.5% | 7.6% | - |
| Value Creation Index ⓘ | -1.3 | -0.5 | -0.5 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | ||||
| Sales ⓘ | 0.6 | 1.6 | 1.9 | 2 |
| Sales YoY Gr. | - | 155.6% | 19.3% | - |
| Adj EPS ⓘ | -0.9 | 0.3 | 0.7 | 0.9 |
| YoY Gr. | - | NA | 140% | - |
| BVPS (₹) ⓘ | 5.6 | 6.1 | 11.4 | 51.3 |
| Adj Net Profit ⓘ | -1 | 0.3 | 0.8 | 1 |
| Cash Flow from Ops. ⓘ | -0.3 | 2.3 | 1.9 | - |
| Debt/CF from Ops. ⓘ | -21.7 | 5.2 | 6.2 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | NA | 19.3% | ||||
| Adj EPS ⓘ | NA | NA | NA | 140% | ||||
| BVPSⓘ | NA | NA | NA | 87.8% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|
| Return on Equity % ⓘ | -16.8 | 5.2 | 8.4 | 2.8 |
| Op. Profit Mgn % ⓘ | -17.1 | 50.8 | 30.5 | NAN |
| Net Profit Mgn % ⓘ | -161.7 | 20.2 | 41.6 | 69.8 |
| Debt to Equity ⓘ | 1.2 | 1.8 | 1 | - |
| Working Cap Days ⓘ | 0 | 2,207 | 2,660 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 363 | 238 | 0 |
Return on Equity has increased versus last 3 years average to 2.80%
Debt to equity has declined versus last 3 years average to 0.95
Sales growth has been subdued in last 3 years 0.00%
Net Profit has been subdued in last 3 years 0.00%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.9 | 5 |
| TTM Sales (₹ Cr.) | 1.9 | 43.9 |
| BVPS (₹.) ⓘ | 51.3 | 10 |
| Reserves (₹ Cr.) ⓘ | 64 | - |
| P/BV ⓘ | 2.59 | 13.30 |
| PE ⓘ | 153.20 | 26.67 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 205 |
| Equity (₹ Cr.) | 15.4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 84.6 |
| Pledged * | 0.00 | 0.00 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|
| Sales | 1 | 2 | 2 |
| Operating Expenses ⓘ | 1 | 1 | 1 |
| Manufacturing Costs | 0 | 0 | 0 |
| Material Costs | 0 | 0 | 0 |
| Employee Cost | 0 | 0 | 1 |
| Other Costs ⓘ | 0 | 0 | 1 |
| Operating Profit ⓘ | 0 | 1 | 1 |
| Operating Profit Margin (%) | -49.4% | 50.8% | 30.5% |
| Other Income ⓘ | 0 | 1 | 2 |
| Interest ⓘ | 1 | 1 | 1 |
| Depreciation ⓘ | 0 | 0 | 0 |
| Exceptional Items ⓘ | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -1 | 0 | 1 |
| Tax ⓘ | 0 | 0 | 0 |
| Profit After Tax | -1 | 0 | 1 |
| PAT Margin (%) | -184.0% | 29.6% | 69.5% |
| Adjusted EPS (₹) | -1.1 | 0.5 | 1.2 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 6 | 7 | 13 | |||||||
| Share Capital ⓘ | 1 | 1 | 1 | |||||||
| Reserves ⓘ | 5 | 5 | 11 | |||||||
| Minority Interest | 0 | 0 | 0 | |||||||
| Debt | 7 | 11 | 12 | |||||||
| Long Term Debt | 7 | 11 | 11 | |||||||
| Short Term Debt | 0 | 0 | 1 | |||||||
| Trade Payables | 0 | 0 | 0 | |||||||
| Others Liabilities ⓘ | 4 | 1 | 1 | |||||||
| Total Liabilities ⓘ | 17 | 19 | 25 | |||||||
Fixed Assets | ||||||||||
| Gross Block | 3 | 3 | 3 | |||||||
| Accumulated Depreciation | 1 | 1 | 1 | |||||||
| Net Fixed Assetsⓘ | 2 | 2 | 1 | |||||||
| CWIP ⓘ | 0 | 0 | 0 | |||||||
| Investmentsⓘ | 6 | 6 | 6 | |||||||
| Inventories | 0 | 0 | 0 | |||||||
| Trade Receivables | 1 | 2 | 1 | |||||||
| Cash Equivalents | 0 | 0 | 0 | |||||||
| Others Assetsⓘ | 7 | 9 | 17 | |||||||
| Total Assets ⓘ | 17 | 19 | 25 | |||||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 0 | 2 | 2 |
| PBT ⓘ | -1 | 0 | 1 |
| Adjustment ⓘ | 1 | 0 | -1 |
| Changes in Working Capital ⓘ | -0 | 1 | 2 |
| Tax Paid ⓘ | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | 0 | -6 | -7 |
| Capex | 0 | 0 | 0 |
| Net Investments | 0 | 0 | 0 |
| Others ⓘ | 0 | -6 | -7 |
| Cash Flow From Financing Activityⓘ | 0 | 4 | 5 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 |
| Interest Paid ⓘ | -1 | -1 | -1 |
| Dividend Paid ⓘ | 0 | 0 | 0 |
| Others ⓘ | 1 | 5 | 6 |
| Net Cash Flow ⓘ | 0 | 0 | 0 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -19.14 | 7.62 | 13.94 | |||||||
| ROCE (%) | -2.71 | 10.75 | 10.69 | |||||||
| Asset Turnover Ratio | 0.04 | 0.09 | 0.09 | |||||||
| PAT to CFO Conversion(x) | N/A | N/A | 2 | Working Capital Days | ||||||
| Receivable Days | 864 | 405 | 258 | |||||||
| Inventory Days | 0 | 0 | 0 | |||||||
| Payable Days | 0 | 0 | 0 | |||||||
Unihealth Consultancy was incorporated as Private Limited Company under the name ‘Unihealth Consultancy Private Limited’, under the provisions of the Companies Act, 1956 and Certificate of Incorporation was issued by the Registrar of Companies, Mumbai on February 26, 2010. The status of the company was changed to public limited, and the name of the company was changed to ‘Unihealth Consultancy Limited’ vide Special Resolution dated December 19, 2022 and resolution of its Board dated December 05, 2022. The fresh Certificate of Incorporation consequent to conversion was issued on April 26, 2023 by the Registrar of Companies, Mumbai.
The company is promoted by first generation entrepreneurs, Dr Anurag Shah and Dr Akshay Parmar, both being medical professionals, having completed their M.B.B.S from KJ Somaiya Medical College and Research Centre, Mumbai, in 2010. Unihealth Pharmaceuticals, a subsidiary of Unihealth Consultancy, is in the business of procuring and exporting pharmaceutical and medical consumable products. The company exports and supplies these products mainly to Victoria Hospital (Joint Venture of Unihealth Consultancy) in Uganda, UMC Global Health (Joint-Venture of Unihealth Consultancy) in Nigeria and Biohealth (Subsidiary of Unihealth Consultancy) in Tanzania.
Unihealth Consultancy is a healthcare service provider based out of Mumbai, India and have operational presence in multiple countries across the African continent. Its business segments include Medical Centres, Hospitals, Consultancy Services, Distribution of Pharmaceutical & Medical Consumable Products and Medical Value Travel. Under the flagship ‘UMC Hospitals’ brand, it operates a combined capacity of many operational hospital beds across its two multi-speciality facilities i.e. UMC Victoria Hospital in Kampala, Uganda, and UMC Zhahir Hospital in Kano, Nigeria. In addition to these, it operates ‘Unihealth Medical Centre’ a dedicated dialysis facility, in Mwanza, Tanzania.
Business area of the company
The company is a healthcare service provider based out of Mumbai, India, and has an operational presence in multiple countries across the African continent.
Awards & recognitions
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
